Calling all investigators focused on addressing elimination in HIV/HCV co-infected and high-risk individuals! Gilead’s HIV/HCV No Co-Infection (NoCo) Program intends to support these micro-elimination efforts by giving up to $600,000 per research proposal. 

The Letter of Intent submission window closes Monday 8/20. To find out more about the HIV/HCV NoCo Program, and to submit, click here